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School of Medicine hosts U.S. Senate field 
hearing on women's health initiatives 
Sen. Edward M. Kennedy chaired a U.S Senate Labor and Hu-
man Resources Committee field hearing on women's health re-
search at the School of Medicine on Jan. 11, acknowledging at 
the outset that there is a dire need to boost federal funding for 
women's health research. 
Speaking to some 350 to 400 members of the Medical Center 
community in the Hiebert Lounge, National Institutes of Health 
Director Bemadine Healy, M.D., provided an overview of the 
NIH's mission to bolster the lagging research in the area of 
women's health. Her remarks were followed by the testimony of 
five other prominent female scientists, including two members 
of the School of Public Health faculty, Hortensia Amaro, Ph.D., 
an associate professor of social and behavioral sciences, and 
Lynn Rosenberg, Sc.D., a professor of epidemiology. 
"Our knowledge of many common disorders is based almost 
entirely on studies that have used men as the standard to deter-
mine research priorities and to evaluate the efficacy to treat-
ments," said Healy. "As a result, judgments regarding 
prevention, interventions and treatment therapies for women 
have sometimes been inappropriate or lacking." 
This is particularly true of minority and low-income women, 
said Rosenberg. "There is a great need for studies among black 
women and other minority groups." Most of the knowledge 
about the causation and prevention of disease in women has 
come from studies of white, middle-class women whose life-
styles and health risks may be different from those of minority or 
poor women. The lack of knowledge about these populations 
may make treatment and other forms of intervention less effec-
tive, she said. 
Amaro said that while she applauded the Women's Health In-
itiative, a 14-year, $625-million clinical study launched by the 
NIH, it would yield little valuable data on the health problems of 
minority women, because it grouped women from very different 
ethnic minorities into one "non-white" category. Even if the 
data for each minority were reported separately, she said, "the 
sample size for each group will be too small to provide much-
neede(i information about the health problems of women in 
Asian, black, Hispanic and Native American communities." 
Gene therapy shows promise for treating 
sickle cell anemia, betal thalassemia 
Researchers at School of Medicine and Children's Hospital in 
Oakland, Calif., have found a way to tum on a fetal gene in pa-
tients with two of the most common inherited blood disorders— 
Sen. Edward M. Kennedy and National Institutes of Health Director 
Bemadine Healy, MD., address members of the press following the sen-
ate field hearing. (Boston University Photo Services) 
sickle cell anemia and beta thalassemia—^resulting in a promis-
ing treatment for these two devastating diseases. 
The study, published in the Jan. 14 issue of The New England 
Journal of Medicine, shows that a compound called arginine 
butyrate safely and effectively stimulates the production of fetal 
globin, which, in the developing fetus, substitutes for beta glo-
bin, a component of hemoglobin that is defective in patients with 
these diseases. The trial was a Phase I/II investigation, which 
was designed to test the safety and, to some extent, the efficacy 
of the drag. Douglas V. Faller, Ph.D., M.D., director of the Can-
cer Center, was a key investigator in the study. 
While the Food and Drag Administration requires that the 
drag be tested in larger groups of people before it can be li-
censed for use, its effect on the six patients studied was so pro-
found that two requested and received "compassionate approval" 
to continue treatment after the trial ended. One of these patients, 
who received treatment for the longest duration, had a "complete 
reversal" of her disease, said Faller. "Looking at her blood, you 
would not know that she had thalassemia." 
In sickle cell anemia, the defective beta globin—^which, along 
with alpha globin, makes up hemoglobin, the oxygen-carrying 
protein in red blood cells—causes red blood cells to sickle, or 
form crescent shapes. In beta thalassemia patients, the beta glo-
bin gene is either missing or the protein is not produced in suffi-
cient quantities. This results in an overproduction of alpha 
globin, which is toxic to red blood cells. 
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Arginine butyrate, which in this study was studied and shown 
to be safe in people ranging in age from three to 27 years, works 
by stimulating the production of fetal globin, which in tum sup-
presses the synthesis of beta globin in patients with sickle cell 
disease and prevents the sickling of the red blood cells. In beta 
thalassemia patients, the fetal globin substitutes for the missing 
beta globin. 
Clinical studies in Saudi Arabia in the 1970s found that cer-
tain populations of people had the sickle cell mutation, but 
showed no signs of the disease. An analysis of their blood re-
vealed that, in addition to the defective beta globin, they were 
also synthesizing fetal globin, a finding that suggested that the 
continued expression of fetal globin after birth could lessen the 
effects of sickle cell disease. 
These findings led Faller and Oakland pediatric hematologist 
Susan Perrine, M.D., the principal investigator of this project, to 
seek populations of infants in which the normal fetal globin 
switch was inhibited. In 1985, they found that infants of diabetic 
mothers did not begin the switch in utero. Once the infant was 
delivered, the switch occurred rapidly, a finding that suggested 
that an environmental factor present during gestation was some-
how preventing the switch. After analyzing several possible fac-
tors, Perrine and Faller found that butyrate, a fatty acid in the 
plasma of the mother, was inhibiting the globin switch. It was 
this discovery that eventually led to the development of the ar-
ginine butyrate infusion. 
"This (kug acts by activating a dormant fetal gene in the adult, 
and may be the first example of a new type of therapy for genetic 
disease, in which drags are designed to regulate gene expres-
sion," noted Faller. He said that a Phase n trial of the arginine 
butyrate infusion already has begun in California and elsewhere 
and that a Phase I trial of an oral version of the drag would begin 
here shortly. The Phase I trial of the oral version already has be-
gun at several other sites in the United States and Canada. 
Until now, the only definitive treatment for both diseases has 
been a bone marrow transplant, a very expensive procedure—it 
can cost between $250,000 and $1 million—for which fewer 
than one in four patients is physically eligible. Although it has 
been used in cancer patients for years, transplantation is still ex-
perimental for sickle cell and thalassemia patients. Because it is 
so risky, transplantation is used only in adults who are suffering 
acutely from the effects of their disease. 
Research shows oncogenic potential 
for Hox gene 7.1 
In one of the first investigations to examine the role of a particu-
lar Hox—or homeobox-containing—gene at the cellular level, 
three School of Medicine researchers have found that forced ex-
pression of Hox gene 7.1 in muscle cells delays or prevents en-
tirely their ability to differentiate, or become specialized cells 
with specific roles, thereby promoting the proliferation of these 
cells. These findings, published in the Dec. 3 issue of Nature, 
suggest that Hox 7.1 has oncogenic potential. 
Hox genes were first cloned in Drosophila, or fruit flies, in the 
late 1970s and were linked to changes in pattern formation. 
Since then, research has established the existence of related 
A reception was held recently at the School in honor of Dorothy C. 
Keefer, registrar and coordinator for advanced standing admissions, 
who retired in January. An alumna of Boston University, Keefer had a 
long and successful career at the Medical Center for 46 years, the last 
22 of which were spent as registrar. Pictured at the reception with 
Keefer is Dean Aram V. Chobanian. (photo by Educational Media Sup-
port Center) 
genes in vertebrates. However, how Hox genes act at the cellu-
lar level remains unclear. While earlier studies have shown that 
Hox 7.1 is associated with cell proliferation, this is perhaps the 
first time that the gene has been introduced into cells that nor-
mally differentiate. Under the direction of principal investigator 
David Sassoon, Ph.D., an assistant research professor of bio-
chemistry, this report confirms Hox 7.rs role in regulating cell 
growth. 
This in vitro investigation also confirmed that the transfected 
cells were capable of anchorage-independent cell growth, one 
characteristic of tumor cells that distinguishes them from other 
cell types. Unlike normal cells, tumor cells do not need to an-
chor themselves to anything to grow, allowing them to migrate 
freely in the body. Moreover, when the transfectant cell show-
ing the highest rate of growth in soft agar was injected into nude 
mice, it produced tumors at all injection sites within two-and-a-
half months. 
'Hox 7.1 was behaving like an oncogene," said Sassoon. He 
noted that while several recent studies found that two other Hox 
genes, Hox 2.4 and Hox 1.1 also were associated with tumor for-
mation, not all Hox genes were oncogenic. The effects of Hox 
7.1 on cell differentiation were specific: The study found that a 
closely related Hox gene, Hox 8.1, failed to have a similar effect. 
Hox genes are beUeved to control the way in which body pat-
terns are formed, by producing a protein that binds to DNA, 
thereby turning other genes on and off in a precise sequence. 
Scientists believe Hox genes play a significant role in determin-
ing the fate of a cell by controlling what type of cell it eventually 
will become and where it will be positioned in the body, a proc-
ess that allows an individual to develop from an embryo to adult. 
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School of Medicine to participate in 
Generalist Physician Initiative 
The School of Medicine was among 18 medical schools recently 
awarded grants from the Robert Wood Johnson Foundation to 
participate in the Generalist Physician Initiative, an effort de-
signed by the foundation to counter a national shortage of gen-
eral physicians by devising ways to encourage medical students 
to enter generalist careers in medicine. 
Working with its affiliated hospitals, community health cen-
ters, agencies and community leaders, the School hopes to pro-
vide incentives for 50 percent of its graduates to choose careers 
in family medicine, pediatrics or general internal medicine by 
the year 2000. It plans to to develop a program to help pay the 
medical education costs of future generalist physicians, who 
often make less money than medical specialists. 
The Robert Wood Johnson Foundation is the nation's largest 
philanthropic organization dedicated to improving the health and 
health care of Americans. 
School of Public Health holds third 
annual 'right-to-die' conference 
The School of Public Health held its third annual conference on 
the "right to die" on Dec. 9 in the Keefer Auditorium. The con-
ference addressed such issues as the right to refuse treatment. 
Three School of Public Health students placed second in the Secretary's 
Award for Innovations in Health Promotion and Disease Prevention, 
sponsored by the Department of Health and Human Services. The stu-
dents' paper was titled "Cervical Cancer Prevention Project in the In-
ner City Communities ofRoxbury and Jamaica Plain, Massachusetts," 
and will be published in the spring edition of Public Health Reports. 
Pictured at the awards ceremony in Washington are, from left, the stu-
dents' faculty advisor, Daniel Merrigan, Ed J)., an assistant professor of 
public health; student Andrea Rudolph; Robert G. Harmon, administra-
tor of the Health Resources and Services Administration; students 
Michelle Bordeu and Victoria Simone Kahan; and James O. Mason, 
MD., DrP.H., assistant secretary for health. 
physician-assisted suicide, religion and health-care proxies, and 
other issues involving a patient's right to die. 
During the conference, George J. Annas, J.D., M.P.H., co-di-
rector of the School's Law, Medicine and Ethics Program, and 
Charles H. Baron, LL.B., Ph.D., of Boston CoUege Law School, 
debated the issue of physician-assisted suicide. Rabbi Joseph 
Polak of the B'nai B'rith Hillel Foundation and the Rev. Russell 
E. Smith of the Pope John Center addressed the topic of reUgion 
and health-care proxies. 
ACS research grants available 
through the Cancer Center 
The Cancer Center at Boston University Medical Center has 
been awarded an institutional grant from the National Chapter of 
the American Cancer Society to encourage young investigators 
(junior faculty) to carry out cancer-related research. 
The primary purpose of the grant is to provide "seed" money 
to allow the initiation of promising new projects or novel ideas 
that will serve as the basis for future grant apphcations from 
other programs. The awards will vary according to the needs of 
the investigator and should not exceed $12,(XX). The majority of 
allocations will be made to persons who have not received prior 
grant support. 
Applications will be awarded on a competitive basis and 
evaluated according to criteria described in the application 
forms. Application forms are available from the Cancer Center 
office, E-124, x4173 (638-4173). 
The deadline for applications is April 1,1993. 
Alpert appointed to Governing Council 
of Institute of Medicine 
Joel J. Alpert, M.D., chairman of the Department of Pediatrics, 
recently was elected to a three-year term on the goveming coun-
cil of the Institute of Medicine, a component of the National 
Academy of Sciences. As one of 21 members of the goveming 
council, Alpert will be helping to guide the activities of the Insti-
tute of Medicine. 
Freddo presents Fry Award Lecture 
Thomas F. Freddo, O.D., Ph.D., an associate professor of oph-
thalmology, pathology and anatomy and director of the Eye Pa-
thology Laboratory, presented the 1992 Glenn A. Fry Award 
Lecture at the American Academy of Optometry meeting held in 
Orlando in December. The title of Freddo's presentation was 
"Aqueous Humor Proteins: A Key for Unlocking Glaucoma?" 
Freddo was selected to present the lecture by the academy for 
his achievements in eye/vision research. 
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Upcoming CME courses 
The following is a list of upcoming courses sponsored by the De-
partment of Continuing Medical Education: 
Recent Advances in Diagnosis and Management of Infectious 
Diseases in Children will be held on March 20 at the Marriott 
Long Wharf Hotel in Boston. 
Controversies in Medicine will be held from March 22 
through March 26 at the Silvertree Hotel in Smowmass Village, 
Colo. 
Cardiology for the Non-Cardiologist: An Approach for the 
1990s will take place at the Royal Sonesta Hotel in Cambridge 
from April 15 through April 16. 
On April 23, The Thyroid: 1993 Update for the Non-Endocri-
nologist will be hied at the Ritz Carlton Hotel in Boston. 
Minimal Access Gastrointestinal Surgery will be held from 
April 15 through April 16 at Boston University Medical Center. 
From April 22 through April 24, Athletic Foot Injuries will be 
held at the Sonesta Beach Hotel in Hamilton, Bermuda. 
Current Clinical Pediatrics will be held from April 26 
through April 30 at the Hilton Resort in Hilton Head, S.C. 
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